Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Investigation of the Structure–Activity Relationships of Psilocybin Analogues
Adam K. Klein, Muhammad Chatha, Lauren J. Laskowski, et al.
ACS Pharmacology & Translational Science (2020) Vol. 4, Iss. 2, pp. 533-542
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
Natalie Hesselgrave, Timothy A. Troppoli, Andreas B. Wulff, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 17
Open Access | Times Cited: 259
The neural basis of psychedelic action
Alex C. Kwan, David E. Olson, Katrin H. Preller, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 11, pp. 1407-1419
Closed Access | Times Cited: 166
The promises and perils of psychedelic pharmacology for psychiatry
Tristan McClure‐Begley, Bryan L. Roth
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 463-473
Closed Access | Times Cited: 139
A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Vern Lewis, Emma M. Bonniwell, Janelle K. Lanham, et al.
Cell Reports (2023) Vol. 42, Iss. 3, pp. 112203-112203
Open Access | Times Cited: 68
Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential
Jason Wallach, Andrew B. Cao, Maggie M. Calkins, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 44
Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
Grant C. Glatfelter, Eline Pottie, John S. Partilla, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 11, pp. 1181-1196
Open Access | Times Cited: 55
Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response
I. Erkizia-Santamaría, R. Alles-Pascual, Igor Horrillo, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113612-113612
Open Access | Times Cited: 50
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1329-1329
Open Access | Times Cited: 35
Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder
Sandeep Singh, Alexander Botvinnik, Orr Shahar, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2AReceptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter
Laura B. Kozell, Amy J. Eshleman, Tracy L. Swanson, et al.
Journal of Pharmacology and Experimental Therapeutics (2023) Vol. 385, Iss. 1, pp. 62-75
Open Access | Times Cited: 23
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
Antonin Rouaud, Abigail E. Calder, Gregor Hasler
Journal of Psychopharmacology (2024) Vol. 38, Iss. 3, pp. 217-224
Open Access | Times Cited: 12
Psychedelic-like Activity of Norpsilocin Analogues
Alexander M. Sherwood, Elise K. Burkhartzmeyer, Samuel E. Williamson, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 2, pp. 315-327
Open Access | Times Cited: 9
Rapid-acting antidepressant drugs modulate affective bias in rats
Justyna K. Hinchcliffe, Sarah A. Stuart, Christian M. Wood, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 729
Open Access | Times Cited: 8
Molecular insights into psychedelic drug action
Samuel T. Slocum, Jeffrey F. DiBerto, Bryan L. Roth
Journal of Neurochemistry (2021) Vol. 162, Iss. 1, pp. 24-38
Open Access | Times Cited: 42
Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs
Michael J. Cunningham, Hailey A. Bock, Inis C. Serrano, et al.
ACS Chemical Neuroscience (2022) Vol. 14, Iss. 1, pp. 119-135
Open Access | Times Cited: 37
Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents
Erika Plazas, Nicoletta Faraone
Biomedicines (2023) Vol. 11, Iss. 2, pp. 461-461
Open Access | Times Cited: 21
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Michael Tagen, Daniel Mantuani, Liron van Heerden, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 9, pp. 876-890
Closed Access | Times Cited: 20
Cardiovascular safety of psychedelic medicine: current status and future directions
Agnieszka Wsół
Pharmacological Reports (2023) Vol. 75, Iss. 6, pp. 1362-1380
Open Access | Times Cited: 20
Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala
Thomas J. Kelly, Emma M. Bonniwell, Lianwei Mu, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 5, pp. 854-863
Closed Access | Times Cited: 16
In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin
N. Jones, Laura M. Wagner, Molly C. Pellitteri Hahn, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 7
In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5‐HT2AR
Eline Pottie, Christophe P. Stove
Journal of Neurochemistry (2022) Vol. 162, Iss. 1, pp. 39-59
Open Access | Times Cited: 25
“Biosynthesis of psilocybin and its nonnatural derivatives by a promiscuous psilocybin synthesis pathway in Escherichia coli”
Jessica E. Flower, William E. Gibbons, A. Adams, et al.
Biotechnology and Bioengineering (2023) Vol. 120, Iss. 8, pp. 2214-2229
Open Access | Times Cited: 15
Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells
Gregory Ian Robinson, Dongping Li, Bo Wang, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 8, pp. 6743-6774
Open Access | Times Cited: 14
Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties
Pol Puigseslloses, Núria Nadal‐Gratacós, Gabriel Ketsela, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 8, pp. 2346-2358
Open Access | Times Cited: 4
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
I. Erkizia-Santamaría, Igor Horrillo, J. Javier Meana, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111249-111249
Closed Access
Page 1 - Next Page

Scroll to top